Other Events ·
Lexaria Bioscience Corp. received a delisting notification from Nasdaq on August 4, 2026, for failing to maintain the…
LEXXLexaria Bioscience Corp.
Lexaria Bioscience Corp. received a delisting notification from Nasdaq on August 4, 2026, for failing to maintain the $1.00 minimum bid price requirement within its compliance period. The company had completed a reverse stock split effective August 3, 2026, which raised the share price above the threshold. Lexaria has filed a hearing request and paid the associated fee to suspend the delisting pending review. The company expects to regain compliance with Nasdaq rules before any potential hearing date. Lexaria Bioscience Corp. operates in the biotechnology industry, focusing on cannabis-derived therapeutics.